J. Naidoo Et Al. , "Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Naidoo, J. Et Al. 2020. Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15 .
Naidoo, J., Vansteenkiste, J. F., Faivre-Finn, C., Ozguroglu, M., Murakami, S., Hui, R., ... Quantin, X.(2020). Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.
Naidoo, Jarushka Et Al. "Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Naidoo, Jarushka Et Al. "Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Naidoo, J. Et Al. (2020) . "Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.
@article{article, author={Jarushka Naidoo Et Al. }, title={Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2020}